Methods for identification and prediction of multiple sclerosis disease and therapy response
AssigneesUniversity of Utah Research Foundation, Lineagen, Inc.
InventorsJohn W. Rose, Mark F. Leppert
Life of this patent
Estimating the term…
Abstract
Methods and compositions for diagnosing multiple sclerosis (“MS”) in an individual or the predisposition or risk of MS, and for the prediction of the response to treatment of MS in an individual. More particularly, methods and compounds for the use of clinical, neuroradiological, genetic, biological and/or immunological markers as prognostic indicators, diagnostic markers, or predictors of response to MS therapy.
Claims30
A method of determining the susceptibility to multiple sclerosis (MS) in an individual, the method comprising:
- assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.:
- 1-171;
- wherein the presence in the individual of the at least one allele of a SNP associated with MS is indicative that the individual is susceptible to MS.
A method of determining the MS disease state of an individual, the method comprising:
- assaying the individual for at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.:
- 1-171;
- detecting in the individual the at least one allele of a SNP associated with MS;
- wherein detecting in the individual the at least one allele of a SNP associated with MS is indicative of the MS disease state of the individual, wherein the MS disease state is selected from the group consisting of Relapsing-Remitting (RR), Primary-Progressive (PP), Secondary-Progressive (SP), and Progressive-Relapsing (PR).
A method of predicting the response of an individual to at least one MS therapy, the method comprising:
- detecting in the individual at least one anti-thyroid antibody, wherein the presence of the at least one anti-thyroid antibody is indicative of the response to the at least one MS therapy.
An in vitro diagnostic product comprising:
- at least one laboratory test for assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.:
- 1-171;
- and
- at least one laboratory test for assaying for the presence or absence in the individual of at least one biomarker associated with MS.
An in vitro diagnostic product for indicating the susceptibility of MS in an individual, the product comprising:
- at least one laboratory test for assaying for the presence in the individual of at least one allele of a SNP associated with MS, wherein the at least one allele of a SNP associated with MS is located within a sequence selected from the group consisting of sequences identified by SEQ ID NOS.:
- 1-171;
- at least one laboratory test for assaying for the presence or absence in the individual of at least one biomarker associated with MS;
- wherein the presence in the individual of the at least one allele of a SNP associated with MS, and the presence in the individual of the at least one biomarker associated with MS, is indicative that the individual is susceptible to MS.
Dependencies are inferred from the claim text.